HRAS and cancer: We therefore sought to better molecularly characterize the mechanisms of resistance to single and combined MEKi and ERKi in oncogenic KRAS-, HRAS- or BRAF-driven cancer cells by focusing analyses on potential rewiring of intracellular signaling cascades.